Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Alzheimer’s Diagnosis In Men Linked To Loss Of Y Chromosome

XTALKS VITALS NEWS

Alzheimer's

The researchers believe that the loss of Y could be a biomarker for Alzheimer’s, allowing physicians to diagnose the disease in its early stages.

Share this!

May 25, 2016 | by Sarah Massey, M.Sc.

A global research team has shown that men whose red blood cells are lacking a Y chromosome – a phenomenon known as loss of Y – may be more susceptible to developing Alzheimer’s. The researchers believe that the loss of Y could be a biomarker for Alzheimer’s, allowing physicians to diagnose the disease in its early stages.

The Y chromosome contains the genetic information necessary for many of the factors that make an individual physiologically male – including development of the testes - but in some men, their Y chromosome begins to degenerate as they age. As men tend to live shorter lives compared to women, and men are more likely to develop non-sex-linked cancers, this loss of Y may explain the differences in mortality between the sexes.

In order to investigate the potential link between loss of Y and Alzheimer’s, Professors Lars Forsberg and Jan Dumanski, from the Department of Immunology, Genetics, and Pathology at Uppsala University, Sweden, set up a collaboration with researchers in the UK, France, the US and Canada. Forsberg’s previous research interests included determining what effects the loss of the Y chromosome had on cancer development and progression.

“The idea for this research project came to me when I was writing our first paper on the relationship between loss of Y and the development of non-blood cancers,” said Forsberg. “In thinking about the process known as immunosurveillance - the body's ability to fight disease development throughout life - I found that it had been well studied in Alzheimer's disease, and hence it occurred to me that loss of Y might be involved in this disease too.”



The researchers studied the prevalence of Y chromosomes in the red blood cells of 3,300 men aged 37 to 96. Approximately 17 percent of the men showed a loss of Y in a minimum of 10 percent of their red blood cells.

The researchers found that elderly men more commonly displayed loss of Y. While the study contained a wide age range, the average age for study participants was 73.

Individuals with a pre-existing Alzheimer’s diagnosis were more likely to have a loss of Y. Interestingly, those identified as having a loss of Y were more likely to develop Alzheimer’s in the follow-up period after the study.

The researchers suggest that the degraded Y chromosome may lower the red blood cell’s ability to function during an immune response. Regardless, the researchers say that loss of Y could act as a biomarker to encourage physicians to begin neurological testing for Alzheimer’s.

More than 5 million people suffer from Alzheimer’s in the US alone; this number is expected to rise to 14 million by 2050.


Keywords: Alzheimer's, Cancer, Biomarker


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Canadian Regulator Recalls Pie Shells Over E. Coli Contaminated Flour

April 28, 2017 - Multiple brands of pie and tart shells are being recalled in Canada after the flour used to manufacture them was linked to 28 cases of illness due to infection with E. coli O121.

Featured In: Food News


FDA Sends Warning Letters to Manufacturers of Fake Cancer Drugs

April 27, 2017 - The FDA is cracking down on the sale of illegal cancer drugs by sending warning letters to 14 US companies selling the unapproved products.

Featured In: Life Science News, Drug Safety News


Womb-Like Device Could Increase Survival of Premature Babies

April 27, 2017 - Researchers at the Children's Hospital of Philadelphia (CHOP) have developed a womb-like device which mimics the environmental conditions found inside the uterus.

Featured In: Life Science News, Medical Device News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Technology Solutions for Late Phase Research: Optimising Real World Data Assets


Serialization for Late Starters – With Live Industry Research Results


Clinical Not All Antioxidants Are Created Equal: Astaxanthin, The Antioxidant Powerhouse


The New Gold Standards of IRT Delivery for Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.